Press releases 2014

December 8, 2014

Leading Bone Repair Company BONESUPPORT and Regenerative Medicine Company Orthocell Ltd Announce a Heads of Agreement

September 24, 2014 

Twelve-Month Follow-Up Of CERAMENT™ With Gentamicin Confirms Significant And Sustained Eradication Of Chronic Infection And Demonstrated Formation Of New Bone

September 9, 2014

CERAMENT™ With Antibiotics To Be Featured Prominently At 33rd Annual Meeting Of The European Bone & Joint Infection Society (EBJIS)

August 5, 2014 

CERAMENT™|G Featured In Documentary ‘The Orthopaedic Revolution: Treating Osteomyelitis’

June 19, 2014

BONESUPPORT AB Announces CHUV In Switzerland Initiates Study Of CERAMENT™|G For One-Stage Surgical Revision Of Bone Infections

April 30, 2014

New CERAMENT™ App Available on App Store – Features clinical indications for CERAMENT™|BONE VOID FILLER

April 15, 2014

First CERAMENT™|G Study With Local Gentamicin Elution Shows Safe Bone Healing With Effective New Bone Ingrowth In Osteomyelitis Patients

March 12, 2014

CERTiFy (CERAMENT™|Tibia Fracture) Study Protocol Published In TRIALS

March 11, 2014

BONESUPPORT AB Announces New Drilling Performance Capability For CERAMENT™|BONE VOID FILLER

February 20, 2014

Launch Of New CERAMENT™|G Registry To Collect Data In The Management Of Bone Infection


Notes to Editor



BONESUPPORT AB has developed CERAMENT™ as an innovative range of radiopaque injectable osteoconductive bioceramic products that have a proven ability to heal defects by remodeling to host bone in six to twelve months. Our products are effective in treating patients with fractures and bone voids caused by trauma, infection, disease or related surgery. Our lead product, CERAMENT™|BONE VOID FILLER (BVF) addresses important issues facing health care providers, such as avoiding hospital readmissions and revision surgery that result from failed bone healing and infection caused by residual bone voids. CERAMENT|BVF is commercially available in the U.S., EU, S.E. Asia and the Middle East.

CERAMENT‘s distinctive properties as a drug eluting material have been validated in clinical practice by CERAMENT™|G and CERAMENT™ V, the first CE-marked injectable antibiotic eluting bone graft substitutes. These products provide local sustained delivery of gentamicin and vancomycin, respectively. The local delivery feature enables an initial high concentration of antibiotics to the bone defect and then a longer sustainable dose above the minimal inhibitory concentration (MIC) to protect bone healing and promote bone remodeling.

CERAMENT|G and CERAMENT™ V have demonstrated good results in patients with problematic bone infections including osteomyelitis. They are also used prophylactically in patients who are at risk for developing infection. CERAMENT|G and CERAMENT™ V are available in the EU.

BONESUPPORT AB was founded in 1999 by Prof. Lars Lidgren, an internationally respected scientist who has been the President of various musculoskeletal societies. BONESUPPORT’s mission is to bring people with bone and joint diseases back to an active life. The company is based in Lund, Sweden.

BONESUPPORT™ is a registered trademark.

Contact Information

Citigate Dewe Rogerson

David Dible, Andrea Bici, Mark Swallow

+44 (0)20 7282 2949/1050/2948